Precision biosciences stock.

We would like to show you a description here but the site won’t allow us.Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene …For some Precision Biosciences executives and investors, optimism is in the air. Precision (Nasdaq: DTIL) made its debut on the Nasdaq stock exchange, trading 9 percent over the initial offering ...Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update. March 15, 2022 at 7:00 AM EDT. ... Weighted average shares of common stock outstanding - basic and diluted 58,688,102 52,031,740 Precision Biosciences, Inc. Consolidated Balance Sheets Data ...

Additionally, Precision announced a common stock offering yesterday. The company will “sell 35,971,224 shares of its common stock at a price of $1.39 per share.”Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina.Discover historical prices for DTIL stock on Yahoo Finance. View daily, weekly or monthly format back to when Precision BioSciences, Inc. stock was issued.

We can see from the most recent balance sheet that Precision BioSciences had liabilities of US$59.7m falling due within a year, and liabilities of US$118.1m due beyond that. Offsetting this, it had US$189.6m in cash and US$720.0k in receivables that were due within 12 months. So it can boast US$12.6m more liquid assets than total liabilities.

May 31, 2023 · In a report released today, Justin Zelin from BTIG maintained a Buy rating on Precision BioSciences ( DTIL – Research Report ), with a price target of $6.00. The company’s shares opened today ... HC Wainwright Adjusts Price Target on Precision BioSciences to $3 From $5, Keeps Buy Rating. Aug. 17. MT. BMO Capital Downgrades Precision BioSciences to Market Perform From Outperform, Adjusts Price Target to $4 From $7. Mar. 14. MT. Goldman Sachs Adjusts Price Target on Precision BioSciences to $1 From $2, Maintains Neutral Rating. Nov. 10. MT. Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human …In the last 3 months, 4 analysts have offered 12-month price targets for Precision BioSciences. The company has an average price target of $3.25 with a high of $5.00 and a low of $2.00.Nov 1, 2023 · Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies.

The latest price target for Precision BioSciences ( NASDAQ: DTIL) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 3.00 expecting DTIL to ...

Dec 1, 2023 · According to the issued ratings of 3 analysts in the last year, the consensus rating for Precision BioSciences stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for DTIL. The average twelve-month price prediction for Precision BioSciences is $3.00 with a high price target of $4.00 and a low price target of $2.00.

Dec 1, 2023 · Get a real-time Precision BioSciences, Inc. (DTIL) stock price quote with breaking news, financials, statistics, charts and more. According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee …The stock currently has a share float of 51.43%. Precision Biosciences Inc stock is held by 114 institutions, with Great Point Partners LLC being the largest institutional investor. By Jun 29, 2023, it held 6.49% of the shares, which is about 7.47 million shares worth $3.93 million.On December 4, 2023, Precision Biosciences made a groundbreaking announcement in the esteemed journal Nature Metabolism. The publication highlighted their latest …Get a real-time Precision BioSciences, Inc. (DTIL) stock price quote with breaking news, financials, statistics, charts and more.

31 thg 12, 2022 ... Precision BioSciences. 148 views · 11 months ago ...more ... Cramer: This biotech stock could be worth over $100 billion on an FDA approval.Track Precision Biosciences Inc (DTIL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsIf you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.16 thg 8, 2023 ... Precision BioSciences hands global rights to CAR-T candidate; Sagimet closes underwriter's option to buy stock ... Precision BioSciences said ...Company profile page for Precision Biologics Inc including stock price, company news, press releases, executives, board members, and contact information

Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ...

Aug 7, 2023 · DURHAM - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced financial results for the second quarter ended June 30, 2023 and provided a business update. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Precision BioSciences with a $7.75 average price target. See the top stocks recommended by analysts >>Shares of Precision BioSciences (DTIL 0.23%) ... As of 1:40 p.m. EST, the stock had settled to a 16.9% gain. The gene-editing stock is up 70% since the beginning of November.7 ngày trước ... DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ...Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS ® genome editing platform. ARCUS is a highly specific ...DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately ...Nov 6, 2023 · As of November 3, 2023, shares of Precision BioSciences were trading at $0.4256. Over the last 52-week period, the stock has experienced a decline of 68.38%. According to TipRanks, the average price target for DTIL is $2.58, with a high forecast of $4.00 and a low forecast of $1.00. In conclusion, investors will be closely monitoring Precision ...

Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.

According to Biosciences for Farming in Africa, sexual reproduction in plants occurs when pollen from a plant’s stamen reaches the stigma of a flower. The pollen contains sperm cells while the stigma holds the corresponding eggs.

Earnings Summary. For their last quarter, Precision BioSciences (DTIL) reported earnings of -$0.10 per share, beating the Zacks Consensus Estimate of $-0.19 per share. This reflects a positive ...In last trading session, Precision Biosciences Inc (NASDAQ:DTIL) saw 1.34 million shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $0.38 trading at $0.01 or 2.19% at ring of the bell on the day assigns it a market valuation of $45.46M. That closing price of DTIL’s stock is at a discount ...Nov 29, 2023DURHAM - Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and... | March 29, 2023Nov 1, 2023 · Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. Nov 24, 2023 · Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ... Precision BioSciences, Inc. Common Stock (DTIL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. DTIL stock, representing Precision BioSciences Inc, had an interesting performance on September 19, 2023. According to data from CNN Money, the 5 analysts offering 12-month price forecasts for DTIL have a median target of $3.00, with a high estimate of $4.00 and a low estimate of $1.40. This indicates a potential increase of …When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.20 thg 11, 2020 ... Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® ...Precision BioSciences is a clinical stage gene editing company that develops CAR T immunotherapies and gene insertion therapies for genetic and infectious …

Aug 7, 2023 · DURHAM - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced financial results for the second quarter ended June 30, 2023 and provided a business update. 13 thg 4, 2021 ... Do you want to earn up to a 4888583% annual return on your money by two trades per day on Precision Biosciences Inc DTIL Stock? Reading this ...Complete Precision Biosciences Inc. stock information by Barron's. View real-time DTIL stock price and news, along with industry-best analysis. The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Instagram:https://instagram. best technology mutual funds 2023flbr stockblue chip stocks under dollar50sofi bank net worth Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Find real-time DTIL - Precision BioSciences Inc stock quotes, company profile, news and forecasts from CNN Business. how to read a candle chartvoo annualized return The Precision BioSciences stock prediction for 2025 is currently $ 0.180111, assuming that Precision BioSciences shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -53.10% increase in the DTIL stock price. books on effective communication Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Precision BioSciences market cap as of November 07, 2023 is $0.05B . Precision BioSciences market cap history and chart from 2018 to 2023. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares ...